The Sesquiterpene Lactone Dehydroleucodine Triggers Senescence and Apoptosis in Association with Accumulation of DNA Damage Markers

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Costantino, Valeria V ^a   Mansilla, Sabrina F ^c   Speroni, Juliana ^c   Amaya, Celina ^a   Cuello Carrión, Darío ^b   Ciocca, Daniel R ^b   Priestap, Horacio A ^d   Barbieri, Manuel A ^d,e   Gottifredi, Vanesa ^c   Lopez, Luis A ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^d FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^e FAIRCHILD TROPICAL BOTANIC GARDEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DEHYDROLEUCODINE; GAMMA H2AX; HISTONE H2AX; NUCLEAR PROTEIN; PROTEIN 53BP1; SESQUITERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; EMBRYO; FEMALE; HUMAN; HUMAN CELL; PHOSPHORYLATION; SENESCENCE;

APOPTOSIS; CELL AGING; CELL PROLIFERATION; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENETIC MARKERS; HELA CELLS; HUMANS; LACTONES; MITOSIS; SESQUITERPENES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

ARTEMISIA DOUGLASIANA;

EID: 84872318842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053168     Document Type: Article

References (49)

1. Heinrich M, Robles M, West JE, Ortiz de Montellano BR, Rodriguez E (1998) Ethnopharmacology of Mexican asteraceae (Compositae). Annu Rev Pharmacol Toxicol 38: 539-565. 10.1146/annurev.pharmtox.38.1.539 [doi].
2. Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N (2010) What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 15: 668-678. S1359-6446(10)00194-7 [pii];10.1016/j.drudis.2010.06.002 [doi].
3. Robles M, Aregullin M, West J, Rodriguez E (1995) Recent studies on the zoopharmacognosy, pharmacology and neurotoxicology of sesquiterpene lactones. Planta Med 61: 199-203. 10.1055/s-2006-958055 [doi].
4. Crespo-Ortiz MP, Wei MQ (2012) Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012: 247597. 10.1155/2012/247597 [doi].
5. Jordan CT (2006) Searching for leukemia stem cells-not yet the end of the road? Cancer Cell 10: 253-254. S1535-6108(06)00284-4 [pii];10.1016/j.ccr.2006.09.010 [doi].
6. Kawasaki BT, Hurt EM, Kalathur M, Duhagon MA, Milner JA, et al. (2009) Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate 69: 827-837. 10.1002/pros.20931 [doi].
7. Zhou J, Zhang Y (2008) Cancer stem cells: Models, mechanisms and implications for improved treatment. Cell Cycle 7: 1360-1370. 5953 [pii].
8. Dey A, Tergaonkar V, Lane DP (2008) Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. Nat Rev Drug Discov 7: 1031-1040. nrd2759 [pii];10.1038/nrd2759 [doi].
9. Jordan CT (2007) The leukemic stem cell. Best Pract Res Clin Haematol 20: 13-18. S1521-6926(06)00074-0 [pii];10.1016/j.beha.2006.10.005 [doi].
10. Sarkar FH, Li Y (2008) NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 13: 2950-2959. 2900 [pii].
11. Zhang S, Won YK, Ong CN, Shen HM, (2005) Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms. Curr Med Chem Anticancer Agents 5: 239-249.
12. Christensen SB, Skytte DM, Denmeade SR, Dionne C, Moller JV, et al. (2009) A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem 9: 276-294.
13. Denmeade SR, Isaacs JT (2005) The SERCA pump as a therapeutic target: making a smart bomb for prostate cancer. Cancer Biol Ther 4: 14-22. 1505 [pii].
14. Efferth T, (2006) Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 7: 407-421.
15. Nakase I, Gallis B, Takatani-Nakase T, Oh S, Lacoste E, et al. (2009) Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 274: 290-298. S0304-3835(08)00787-8 [pii];10.1016/j.canlet.2008.09.023 [doi].
16. Gopal YN, Chanchorn E, Van Dyke MW (2009) Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 8: 552-562. 1535-7163.MCT-08-0661 [pii];10.1158/1535-7163.MCT-08-0661 [doi].
17. Hehner SP, Heinrich M, Bork PM, Vogt M, Ratter F, et al. (1998) Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J Biol Chem 273: 1288-1297.
18. Gopal YN, Arora TS, Van Dyke MW (2007) Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated. Chem Biol 14: 813-823. S1074-5521(07)00212-8 [pii];10.1016/j.chembiol.2007.06.007 [doi].
19. Liu Z, Liu S, Xie Z, Pavlovicz RE, Wu J, et al. (2009) Modulation of DNA methylation by a sesquiterpene lactone parthenolide. J Pharmacol Exp Ther 329: 505-514. jpet.108.147934 [pii];10.1124/jpet.108.147934 [doi].
20. Woynarowski JM, Konopa J, (1981) Inhibition of DNA biosynthesis in HeLa cells by cytotoxic and antitumor sesquiterpene lactones. Mol Pharmacol 19: 97-102.
21. Priestap HA, Abboud KA, Velandia AE, Lopez LA, Barbieri MA (2011) Dehydro-leucodin: a guaiane-type sesquiterpene lactone. Acta Crystallogr Sect E Struct Rep Online 67: o3470. 10.1107/S1600536811048938 [doi];bg2432 [pii].
22. Giordano OS, Guerreiro E, Pestchanker MJ, Guzman J, Pastor D, et al. (1990) The gastric cytoprotective effect of several sesquiterpene lactones. J Nat Prod 53: 803-809.
23. Cruzado M, Castro C, Fernandez D, Gomez L, Roque M, et al. (2005) Dehydroleucodine inhibits vascular smooth muscle cell proliferation in G2 phase. Cell Mol Biol (Noisy-le-grand) 51: 525-530. 525 [pii].
24. Lopez ME, Giordano OS, Lopez LA, (2002) Sesquiterpene lactone dehydroleucodine selectively induces transient arrest in G2 in Allium cepa root meristematic cells. Protoplasma 219: 82-88.
25. Losinno AD, Morales A, Fernandez D, Lopez LA (2012) Peritubular Myoid Cells from Rat Seminiferous Tubules Contain Actin and Myosin Filaments Distributed in Two Independent Layers. Biol Reprod. biolreprod.111.095158 [pii];10.1095/biolreprod.111.095158 [doi].
26. Sanchez TG, Giordano OS, Lopez LA, Buhler MI (2007) Effect of dehydroleucodine on meiosis reinitiation in Bufo arenarum denuded oocytes. Zygote 15: 183-187. S0967199407004212 [pii];10.1017/S0967199407004212 [doi].
27. Sanchez TG, Lopez LA, Martinez JZ, Buhler MC, Buhler MI (2010) Involvement of the dehydroleucodine alpha-methylene-gamma-lactone function in GVBD inhibition in Bufo arenarum oocytes. Zygote 18: 41-49. S0967199409990086 [pii];10.1017/S0967199409990086 [doi].
28. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078. nature08467 [pii];10.1038/nature08467 [doi].
29. Gottifredi V, Prives C (2005) The S phase checkpoint: when the crowd meets at the fork. Semin Cell Dev Biol 16: 355-368. S1084-9521(05)00035-2 [pii];10.1016/j.semcdb.2005.02.011 [doi].
30. Bartek J, Lukas J (2007) DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19: 238-245. S0955-0674(07)00023-3 [pii];10.1016/j.ceb.2007.02.009 [doi].
31. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
32. Knehr M, Poppe M, Enulescu M, Eickelbaum W, Stoehr M, et al. (1995) A critical appraisal of synchronization methods applied to achieve maximal enrichment of HeLa cells in specific cell cycle phases. Exp Cell Res 217: 546-553. S0014-4827(85)71121-4 [pii];10.1006/excr.1995.1121 [doi].
33. Liu Y, Peterson DA, Kimura H, Schubert D, (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69: 581-593.
34. Cuello-Carrion FD, Ciocca DR, (1999) Improved detection of apoptotic cells using a modified in situ TUNEL technique. J Histochem Cytochem 47: 837-839.
35. Bossy-Wetzel E, Green DR (2000) Detection of apoptosis by annexin V labeling. Methods Enzymol 322: 15-18. S0076-6879(00)22004-1 [pii].
36. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. S0003269776699996 [pii].
37. Lee YJ, Baek JY, Lee BY, Kang SS, Park HS, et al. (2006) 2′-Carboxybenzyl glycosides: glycosyl donors for C-glycosylation and conversion into other glycosyl donors. Carbohydr Res 341: 1708-1716. S0008-6215(06)00136-4 [pii];10.1016/j.carres.2006.03.014 [doi].
38. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92: 9363-9367.
39. Cleaver JE, Feeney L, Revet I (2011) Phosphorylated H2Ax is not an unambiguous marker for DNA double-strand breaks. Cell Cycle 10: 3223-3224. 17448 [pii];10.4161/cc.10.19.17448 [doi].
40. Jones RM, Petermann E (2012) Replication fork dynamics and the DNA damage response. Biochem J 443: 13-26. BJ20112100 [pii];10.1042/BJ20112100 [doi].
41. Aly A, Ganesan S (2011) BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 3: 66-74. mjq055 [pii];10.1093/jmcb/mjq055 [doi].
42. Nurse P (1990) Universal control mechanism regulating onset of M-phase. Nature 344: 503-508. 10.1038/344503a0 [doi].
43. Vicencio JM, Galluzzi L, Tajeddine N, Ortiz C, Criollo A, et al. (2008) Senescence, apoptosis or autophagy? When a damaged cell must decide its path-a mini-review. Gerontology 54: 92-99. 000129697 [pii];10.1159/000129697 [doi].
44. Campisi J, d'Adda di FF (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740. nrm2233 [pii];10.1038/nrm2233 [doi].
45. Liao WL, Turko IV (2009) Accumulation of large protein fragments in prematurely senescent ARPE-19 cells. Invest Ophthalmol Vis Sci 50: 4992-4997. iovs.09-3671 [pii];10.1167/iovs.09-3671 [doi].
46. Narita M, Nunez S, Heard E, Narita M, Lin AW, et al. (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703-716. S009286740300401X [pii].
47. Johnson TM, Meade K, Pathak N, Marques MR, Attardi LD (2008) Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence. Proc Natl Acad Sci U S A 105: 1215-1220. 0706764105 [pii];10.1073/pnas.0706764105 [doi].
48. Xu Y, Zhang J, Chen X (2007) The activity of p53 is differentially regulated by Brm- and Brg1-containing SWI/SNF chromatin remodeling complexes. J Biol Chem 282: 37429-37435. M706039200 [pii];10.1074/jbc.M706039200 [doi].
49. Polo LM, Castro CM, Cruzado MC, Collino CJ, Cuello-Carrion FD, et al. (2007) 11,13-dihydro-dehydroleucodine, a derivative of dehydroleucodine with an inactivated alkylating function conserves the anti-proliferative activity in G2 but does not cause cytotoxicity. Eur J Pharmacol 556: 19-26. S0014-2999(06)01216-7 [pii];10.1016/j.ejphar.2006.10.049 [doi].